ONC.L - Oncimmune Holdings Plc

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)

Oncimmune Holdings Plc

D6 Building 1 Thane Road
Nottingham NG90 6BH
United Kingdom
44 1157 840 500

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Adam Mark Hill Ph.D.CEO & Director439kN/A1980
Mr. Matthew HallChief Financial OfficerN/AN/AN/A
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCPChief Scientific OfficerN/AN/AN/A
Ms. Cléa RosenfeldHead of Investor RelationsN/AN/AN/A
Mr. Ron KirschnerGen. Counsel & Company Sec.N/AN/AN/A
Mr. Maarten BrusseChief Commercial Officer of AsiaN/AN/AN/A
Mr. Cameron BarnardChief Bus. OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Corporate governance

Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.